u/yara_mensah

Small fix — a reference interval is not a treatment target, and the post above uses them interchangeably.

Cosigning on discontinuation. It is a result about tolerability and it gets buried every time.

date of analysis matters as much as the number

Same. The SSA results have been sitting in a tight band across lots, which is the useful shape.

A token symbol identifies an asset, not a network. The same symbol commonly exists on several chains with incompatible address formats, and sending across that boundary is generally unrecoverable.

Stalled for 19 weeks and measured my waist out of stubbornness. It had moved. The scale had not.

three lots beats three tests on one lot

lab reference ranges are not treatment targets

Agreed on the error margin. Quoting a DEXA to one decimal implies a precision the method does not have.

That is a trial average in a supervised population and you are comparing your own scan to it.

Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.

A test transaction costs one extra network fee and verifies the address, the network and the recipient’s crediting process before the main amount moves.

Some lean mass loss accompanies weight loss in any deficit. Resistance training and adequate protein intake are the two interventions with the best evidence for limiting the proportion.

Agreed — protein and resistance training. Everything else in these threads is a rounding error on those two.

a milestone is whatever you decide it is

Adding the obvious one — take it to whoever ordered the panel.

Agreed — and standardising the draw conditions is the cheapest improvement available.

one measurement is a point, two is a line, three is a trend

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

read the endpoint before you read the headline

the clothes change before the number does

Area percent or net peptide content?

draw at the same point in the week if you want comparability

Repeat testing before acting is standard practice for a reason: regression to the mean does a lot of work on single outlying values.

celebrate the boring milestones, they are the durable ones

a mean is not a promise

Text-only posting removes the comparison mechanism that makes image boards difficult, which is why this community adopted the rule and has kept it.

the monotherapy numbers are modest and that is not the point

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

Pasted rather than typed the address, then checked the first and last six characters. Habit now.

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

amylin and GLP-1 are not redundant pathways

Small fix — same supplier, different lot. The two rows in the log are not the same batch.

read the combination arms separately from the monotherapy arms

amylin analogue, different receptor family, different story

How many separate lots does your series cover?

Is that the same lot as the one in the thread from last month?

Batch number and date of analysis?

What was the non-scale thing that told you first?

Slight disagreement: that is a month, not a plateau, and calling it one makes it heavier than it is.